Clinical trials: Recurrent Hepatocellular Cancer
HCC, Minimal Residual Disease
Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC
Hepatocellular carcinoma (HCC) is a leading global cause of cancer-related mortality. While curative resection is pivotal, high postoperative recurrence rates remain a major challenge.
- Conditions
- HCC, Minimal Residual Disease, Recurrence
- Trial name
- NCT07350824
- Testing
- Adjuvant PD-1 inhibitors, Active monitoring
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Tongji Hospital
Recurrent Hepatocellular Carcinoma
TCR-Redirected T Cell Treatment in Patients With Recurrent HBV-related Hepatocellular Carcinoma Post Liver Transplantation
This is a single-arm and open-label study to assess the safety, tolerability and primary efficacy of the HBV specific T cell receptor (HBV/TCR) redirected T cell in patients with recurrent Hepatitis B virus (HBV) related…
- Trial name
- NCT04677088
- Testing
- TCR-T cells
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Xiaoshun He
Hepatocellular Carcinoma, Rapamycin
Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC
To evaluate the clinical effect of rapamycin combined with TACE on early-stage HCC with overexpression of ASPH after radical surgery using randomized controlled study and provide a new anti-recurrence treatment for HCC patients…
- Trial name
- NCT02724332
- Testing
- Rapamycin
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Liver Cancer
Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00514228
- Testing
- sunitinib malate
- Where
- Switzerland
- Volunteers
- 45 people
- Sponsor
- Swiss Cancer Institute
Cancer
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
RATIONALE: Using BG00001 to insert the gene for interferon-beta into a person's pleural cavity may improve the body's ability to fight cancer.
- Trial name
- NCT00066404
- Testing
- recombinant adenovirus-hIFN-beta
- Where
- United States
- Sponsor
- Abramson Cancer Center at Penn Medicine
Hepatocellular Carcinoma (HCC)
Efcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcinoma With High-risk Recurrence Factors
This is a single-center, single-arm, prospective trial to explore the efficacy and safety of postoperative adjuvant hepatic arterial infusion chemotherapy(HAIC) with mFOLFOX in hepatocellular carcinoma with high-risk recurrence…
- Trial name
- NCT07337421
- Testing
- mFOLFOX ：Oxaliplatin,leucovorin calcium,5-fluorouracil
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Northern Jiangsu People's Hospital
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
This first-in-human study evaluates safety, tolerability and distribution of [225Ac] FPI-1966, [111In]-FPI-1967, and vofatamab in patients with FGFR3-expressing solid tumors.
- Conditions
- Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma, Susceptible FGFR3 Genetic Alterations
- Trial name
- NCT05363605
- Testing
- [225Ac]-FPI-1966, [111In]-FPI-1967, vofatamab
- Where
- 6 sites in United States, Australia
- Volunteers
- 6 people
- Sponsor
- Fusion Pharmaceuticals Inc.
Hepatocellular Carcinoma
Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence
To explore the safety and preliminary efficacy of donafenib combined with tislelizumab in adjuvant therapy after radical surgical resection of primary hepatocellular carcinoma with high risk of recurrence.
- Trial name
- NCT05545124
- Testing
- Donafenib + Tislelizumab
- Volunteers
- 32 people
- Sponsor
- Henan Cancer Hospital
Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of dasatinib in treating patients with solid tumors or lymphomas that are metastatic or cannot be removed by surgery.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia, Adult Hepatocellular Carcinoma, Adult Nasal Type Extranodal NK/T-Cell Lymphoma
- Trial name
- NCT00608361
- Testing
- Dasatinib, Pharmacological Study
- Where
- 23 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
DAA in the Risk of Recurrence After Curative Treatment of HCC
For early stage of HCC, surgical resection or radiofrequency ablation (RFA) is the mainstay curative treatments. However, recurrence is still a major issue after the surgery or RFA.
- Trial name
- NCT02959359
- Testing
- Ledipasvir 90mg/Sofosbuvir 400 mg, Ribavirin
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Hepatocellular Carcinoma
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
The primary objective of this study was to evaluate the efficacy of anlotinib hydrochloride capsules combined with penpulimab injection (test group) versus placebo (control group) for adjuvant therapy after radical surgery or…
- Trial name
- NCT05862337
- Testing
- Anlotinib hydrochloride capsules, Penpulimab injection
- Where
- 67 sites in China
- Volunteers
- 480 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Liver Transplant Disorder, Liver Cancer
Deep Learning Model for the Prediction of Post-LT HCC Recurrence
Identifying patients at high risk for recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) represents a challenging issue.
- Conditions
- Liver Transplant Disorder, Liver Cancer, Recurrent Cancer
- Trial name
- TRAIN-AI (NCT05200195)
- Testing
- Liver transplantation
- Where
- Italy
- Volunteers
- 4,026 people
- Sponsor
- European Hepatocellular Cancer Liver Transplant Group
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative…
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer, Extensive Stage Small Cell Lung Cancer
- Trial name
- NCT00031681
- Testing
- 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1
The study is designed to investigate the effect of adjuvant therapy by Sorafenib, Oxaliplatin and S-1 to prevent the tumor recurrence for hepatocellular carcinoma after liver transplantation
- Trial name
- NCT02129322
- Testing
- Sorafenib, S-1, Oxaliplatin
- Where
- China
- Sponsor
- Zhejiang University
HCC
Sorafenib Combined With Arsenical in Treating Patients With Recurrent HCC After Liver Transplantation
To analyze the safety, efficacy and pharmacokinetic characteristics of sorafenib combined with compound huangdai tablets in patients with recurrent hepatocellular carcinoma after liver transplantation
- Trial name
- HCC (NCT04232722)
- Testing
- Arsenicals
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Zhejiang University
Hepatocellular Carcinoma
The Impact on Hepatic Recurrence After Adjuvant Chemotherapy With Intraarterial Infusion of Idarubicin-Lipiodol
The aim of this study is to test whether the realization of 3 courses of intra-arterial chemotherapy of idarubicin-lipiodol without embolization, administered non-selectively in the hepatic artery, following the percutaneous…
- Trial name
- LIDA-ADJ (NCT04178642)
- Testing
- percutaneous destruction of the tumor + Idarubicin-Lipiodol treatment, Percutaneous destruction of the tumor
- Where
- France
- Sponsor
- University Hospital, Montpellier
Resectable Hepatocellular Carcinoma
AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)
This is a Phase 2, open-label, single-arm study of neoadjuvant immune-checkpoint blockade therapy (AK104) combining with TACE for resectable hepatocellular carcinoma.
- Trial name
- NCT05578430
- Testing
- Cadonilimab, TACE, Surgery
- Volunteers
- 54 people
- Sponsor
- Sun Yat-sen University
HCC Patients After Curative Treatment With Low HBV Viral Load
Tenofovir Alafenamide(TAF) Reduces the Risk of Hepatocellular Carcinoma(HCC) Recurrence
Hepatocellular carcinoma(HCC) is prevalent in the hepatitis B virus(HBV) infection endemic areas. For early stage of HCC, surgical resection, radiofrequency ablation (RFA) or microwave ablation (MWA) are the main treatment…
- Trial name
- NCT04290936
- Testing
- Vemlidy® (Tenofovir Alafenamide; TAF)
- Where
- 4 sites in Taiwan
- Volunteers
- 402 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Hepatocellular Carcinoma
Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma
The purpose of this study is to assess toxicities of angiogenic peptide vaccine therapy in treating HLA-A*2402 restricted patients with advanced hepatocellular carcinoma.
- Trial name
- NCT01266707
- Testing
- antiangiogenic paptide vaccine
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Fukushima Medical University
Hepatocellular Carcinoma
Research on Surgery and Micro-Invasive Treatment in Recurrent Primary Liver Cancer
In this study, we intend to divide the subjects who have been confirmed recurrent HCC into two groups: Group A: treatment with pure surgery or Group B: treatment with pure radio frequency.
- Trial name
- NCT00822562
- Testing
- PRFA or PMCT, surgery
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital